Indications

• Symptomatic Bradycardia (see xxxx, [[xxxx]])

---

Pharmacology

• β1-Adrenergic Receptor Agonist (see β1-Adrenergic Receptor Agonists, [[β1-Adrenergic Receptor Agonists]])
  • Positive Chronotropy with Increase in Blood Pressure) -> increased cardiac output
  • Positive Inotropy (with Increase in Blood Pressure) -> increased cardiac output
• β2-Adrenergic Receptor Agonist (see β2-Adrenergic Receptor Agonists, [[β2-Adrenergic Receptor Agonists]])
  • Bronchodilation
  • Vasodilation (with Decrease in Diastolic Blood Pressure): via effects on β2-adrenergic-receptors in arteriolar smooth muscle
• TAAR1 Agonist: effects at this receptor resemble those of trace amines (such as tyramine)

Pharmacodynamics

• Plasma Half-Life: 2 min

Metabolism

• xxxx

---

Administration

• IV: 2-10 ug/min
• PO:
• INH:

Dose Adjustment

• Hepatic:
• Renal:

Risk of Extravasation-Associated Tissue Damage

• Tissue Necrosis

---

Adverse Effects

Cardiovascular Adverse Effects

• Arrhythmias
  • Atrial Fibrillation (AF) (see Atrial Fibrillation, [[Atrial Fibrillation]])
  • Ventricular Tachycardia (VT) (see Ventricular Tachycardia, [[Ventricular Tachycardia]])
• Exacerbation of Myocardial Ischemia (see Coronary Artery Disease, [[Coronary Artery Disease]])
• Hypertension (see Hypertension, [[Hypertension]])
• QT Prolongation without Definite Association with Torsade (see Torsade, [[Torsade]])
• Sinus Tachycardia (see Sinus Tachycardia, [[Sinus Tachycardia]])

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• xxxx